Pain During Chest Tube Withdrawal: Evaluation Using Pan Monitor

Overview

Pain evaluation remains a clinical problem. Pain Monitor allows pain evaluation using the measurement of skin conductance.

Withdrawal of chest tube can be painful and the purpose of the study was to compare auto-evaluation of pain (visual analogic scale) and the index measured by the Pain Monitor.

Full Title of Study: “Pain During Chest Tube Withdrawal: Evaluation Using Pan Monitor in Patients With or Without Epidural Anesthesia”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: May 2014

Interventions

  • Procedure: Chest drain withdrawal
  • Device: Pain Monitor

Arms, Groups and Cohorts

  • Epidural analgesia
    • Postoperative patients with epidural analgesia
  • Oral analgesics
    • Postoperative patients with oral analgesics

Clinical Trial Outcome Measures

Primary Measures

  • Pain monitor evaluation of pain
    • Time Frame: 1 hour
    • Comparison between Pain monitor index and auto-evaluation of pain (numerical scale from 0 -no pain- to 10 – maximal pain)

Secondary Measures

  • Pain intensity
    • Time Frame: 1 hour
    • Evolution of Pain monitor index and of auto-evaluation of pain (numerical scale from 0 -no pain- to 10 – maximal pain) during the chest tube withdrawal

Participating in This Clinical Trial

Inclusion Criteria

  • patients undergoing removal of a chest tube after lung surgery,
  • patients able to indicate the pain score.

Exclusion Criteria

  • pregnancy, lactation ,
  • insulin-dependent diabetes with dysautonomia,
  • central or peripheral neurological disease, agitation,
  • inability to understand the protocol,
  • inability to use the Pain Monitor: skin abnormalities at the site of measurement, pacemaker or implantable defibrillator, condition affecting the sympathetic nervous system, tremor of the extremities,
  • contra-indication to oral morphine ,
  • respiratory failure, severe hepatic insufficiency, intracranial hypertension, epilepsy associations
  • recent administration of neostigmine or of atropine.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Hopital Foch
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Marc Fischler, Study Chair, Hôpital Foch

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.